Weekly Analysts’ Ratings Updates for CAMP4 Therapeutics (CAMP)

Several brokerages have updated their recommendations and price targets on shares of CAMP4 Therapeutics (NASDAQ: CAMP) in the last few weeks:

• 10/10/2026 – CAMP4 Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/5/2026 – CAMP4 Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $15.00 price target on the stock.
• 10/2/2026 – CAMP4 Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/29/2026 – CAMP4 Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/29/2026 – CAMP4 Therapeutics had its price target lowered by Chardan Capital from $6.50 to $6.00. They now have a “buy” rating on the stock.
• 9/17/2026 – CAMP4 Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/2/2026 – CAMP4 Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/17/2026 – CAMP4 Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/14/2026 – CAMP4 Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/14/2026 – CAMP4 Therapeutics was given a new $15.00 price target by UBS Group AG.
• 8/14/2026 – CAMP4 Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $15.00 price target on the stock, up from $12.00.

Insider Activity

In related news, Director Richard Young purchased 16,378 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $1.65 per share, with a total value of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. This trade represents a 9.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Schwab sold 400,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have purchased 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. Company insiders own 21.69% of the company’s stock.

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.